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TO THE EDITOR
A few previous studies have examined
the relationship between germline mela-
nocortin-1 receptor (MC1R) status and
somatic BRAF mutations in melanoma.
Two publications reported strong associa-
tions in three independent populations
(two from Italy and one from San
Francisco) (Landi et al., 2006; Fargnoli
et al., 2008), whereas a more recent
publication found no association in an
Australian population-based study (Hacker
et al., 2010). We report our finding of no
significant association between MC1R
status and BRAF-mutant melanomas in a
population-based study of malignant mel-
anoma in North Carolina.
Participants in this study were
219 cases with first primary invasive
cutaneous melanoma from North Car-
olina, one site in the population-based
Genes, Environment, and Melanoma
(GEM) study (Begg et al., 2006). The
study protocol was approved by the
institutional review board of the Uni-
versity of North Carolina at Chapel Hill.
The Declaration of Helsinki protocols
were followed, and patients gave their
written, informed consent. The partici-
pants were interviewed regarding their
risk factors (Thomas et al., 2007). The
subjects were asked to have the nevi on
their backs counted by a family mem-
ber or friend, using a glossy colored
guide to aid in differentiating between
nevi and other skin lesions.
One dermatopathologist (KB) re-
viewed the tumors for standard histolo-
gical features. The tumors were scored
Abbreviations: adj., adjusted; CI, confidence interval; CSD, chronic sun damage; MC1R, melanocortin-1
receptor; OR, odds ratio; wt, wild type
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for chronic sun damage (CSD) using a 0
to 3þ multipoint scale and dichoto-
mized into melanomas with little histo-
logical evidence of CSD (non-CSD)
(level 0 to 2) and those with histo-
logical evidence of CSD (level 2 to
3þ ), as in Landi et al. (2006). BRAF
mutations in and around codon V600 in
melanomas were determined as pre-
viously described (Thomas et al., 2007).
We sequenced MC1R from buccal
DNA (Kanetsky et al., 2006), and six
cases were excluded because their
germline DNA did not amplify. MC1R
alleles were classified as ‘‘R’’ and ‘‘r’’
according to the nomenclature deve-
loped by Duffy et al. (2004). MC1R
variants were defined as ‘‘R’’ (D84E,
R142H, R151C, R160W, and D294H)
owing to their strong association with
the red hair phenotype in a recent
meta-analysis (Raimondi et al., 2008).
The MC1R c.86_87insA variant was
also included as an ‘‘R’’ variant, be-
cause it results in a truncated, nonfunc-
tional receptor, and patients reported
with red hair have been compound
heterozygous for MC1R stop or frame-
shifts along with an ‘‘R’’ allele (Kennedy
et al., 2001; Beaumont et al., 2008). All
other nonsynonymous MC1R variants
were classified as ‘‘r’’ (V60L, A64T,
92M, D117V, I155T, V156L, R163Q,
R223W, and K278E).
BRAF-mutant tumors were defined
as those found to have mutations in and
around the V600 codon in exon 15.
Odds ratios (ORs) and accompanying
95% confidence intervals (CIs) were
calculated in logistic regression models
using SAS (SAS Institute, Cary, NC,
USA). Age was included as a contin-
uous variable. All significance tests
were two-sided and a P-value of
o0.05 was considered statistically sig-
nificant. Potential interactions were
assessed using likelihood ratio tests
with an a priori a of 0.2 (Selvin,
1996). The likelihood ratio tests were
performed using STATA version 10
(Stata-Corp LP, College Station, TX).
The 213 study cases included in the
analyses had a mean age at diagnosis of
52.1 years and were 54.9% male. The
study included a high percentage (55.9%)
of thin (Breslow thickness o0.75mm)
melanomas. The percentages of histologi-
cal subtypes were 77.5% superficial
spreading melanoma, 4.2% nodular mel-
anoma, 10.3% lentigomalignamelanoma,
0.9% acral lentiginous melanomas, and
7.0% other or unclassifiable melanoma.
The anatomic distribution of the melano-
mas was 15.0% head or neck, 50.2%
truncal, 18.8% upper extremities, and
16.0% lower extremities. The percentage
of non-CSD melanomas was 70.2%.
The presence of any nonsynonymous
germline MC1R variant showed no
association with BRAF-mutant melano-
ma (OR 0.9; 95% CI 0.4–2.3) after adjust-
ing for age at diagnosis, ability to tan,
and back nevus count (Table 1a). Finer
MC1R categorization did not reveal an
association of BRAF-mutant melanoma
with carriage of oneMC1R (r/wt or R/wt)
(adjusted (adj.) OR 1.2; 95% CI 0.5–3.0)
or two MC1R (r/r, R/r, or R/R) (adj. OR
0.7; 95% CI 0.2–1.7) variants.
The analyses were repeated consid-
ering only association with the ‘‘R’’
variants (Table 1b). BRAF-mutant mel-
anoma was not associated with the
presence of any ‘‘R’’ variant (R/R, R/r,
or R/wt) (adj. OR 1.4; 95% CI 0.7–2.6).
Finer categorization of one (R/r, or R/wt)
or two (R/R) ‘‘R’’ variants did not result
in significant associations (adj. OR 1.8;
95% CI 0.9 to 3.6 and adj. OR 0.6; 95%
CI 0.2–1.6, respectively).
Table 1. Germline variants of MC1R and tumor-specific BRAF-mutant melanomas (North Carolina first incident
primary cutaneous melanomas) (N=213)
MC1R1 BRAF mut (n=88) BRAF wt (n=125) OR (95% CI) P-value OR (95% CI)2 P-value
(a) All variants
wt/wt 11 (12.5%) 18 (14%) Reference Reference
Any variant 77 (87.5%) 107 (86%) 1.2 (0.5–2.6) 0.69 0.9 (0.4–2.3) 0.90
wt/wt 11 (13%) 18 (14%) Reference Reference
One variant (r/wt or R/wt) 46 (52%) 53 (42%) 1.4 (0.6–3.3) 0.42 1.2 (0.5–3.0) 0.70
Two variants (r/r, R/r, or R/R) 31 (35%) 54 (43%) 0.9 (0.4–2.2) 0.89 0.7 (0.2–1.7) 0.39
(b) ‘‘R’’ variants
wt/wt, r/wt, or r/r 39 (44%) 58 (46%) Reference Reference
Any ‘‘R’’ variant (R/R, R/r, or R/wt) 49 (56%) 67 (54%) 1.1 (0.6–1.9) 0.76 1.4 (0.7–2.6) 0.35
wt/wt, r/wt, or r/r 39 (44%) 58 (46%) Reference Reference
One ‘‘R’’ variant (R/wt or R/r) 41 (47%) 45 (36%) 1.4 (0.8–2.5) 0.31 1.8 (0.9–3.6) 0.09
Two ‘‘R’’ variants (R/R) 8 (9%) 22 (18%) 0.5 (0.2–1.3) 0.18 0.6 (0.2–1.6) 0.26
Abbreviations: BRAF mut, contains a somatic mutation in or around the V600 codon in BRAF exon 15; BRAF wt, negative for a somatic mutation in BRAF
exon 15; CI, confidence interval; MC1R, melanocortin-1 receptor; OR, odds ratio; wt, wild type.
1MC1R variants defined as ‘‘R’’ (D84E, R151C, R160W, D294H, R142H, and c.86_87insA). All other non-synonymous MC1R variants were defined as ‘‘r’’
(V60L, A64T, V92M, D117V, I155T, V156L, R163Q, R223W, and K278E).
2Logistic regression models adjusted for age at diagnosis, ability to tan, and number of moles on the back.
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We examined the potential interac-
tions of anatomic site (head and arms
versus trunk and legs) and CSD (CSD
versus non-CSD melanoma) as proxy
measures of sun exposure on the
relationship between MC1R status (any
variant) and BRAF-mutant melanoma.
No statistically significant interactions
were found (data not shown).
In a study by Landi et al. (2006),
D84E, R142H, and c.86_87insA were
defined as ‘‘r’’ rather than ‘‘R’’. Reclassi-
fication of these variants as ‘‘r’’ did not
significantly change the results (data not
shown). For purposes of comparison with
cases included by Landi et al. and
Fargnoli et al., we repeated all analyses
excluding two cases with melanomas on
acral skin and four cases with positive or
indeterminate germline CDKN2A muta-
tions (Orlow et al., 2007). These re-
analyses did not reveal any significant
associations (data not shown).
Our data do not support a strong
association of MC1R variants with BRAF
mutations in our North Carolina popula-
tion. Differences in the findings between
studies may be due, in part, to differing
frequencies of distinct MC1R variants
between study populations, which may
not all be similarly associated with BRAF
mutation. Another possibility is that the
risk-modifying effect of MC1R variants
may vary between populations based on
unidentified genetic factors. Climate dif-
ferences, such as ambient sun exposure,
could also influence the relationship
between MC1R status and BRAF-mutant
melanoma. However, despite our study
being the largest to date, the sample sizes
are relatively modest in all the studies,
and further investigation is necessary to
clarify the relationship of germlineMC1R
variants and BRAF-mutant melanomas
among different populations.
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PAX3 Is Extensively Expressed in Benign and Malignant
Tissues of the Melanocytic Lineage in Humans
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TO THE EDITOR
The paired box transcription factor,
paired box 3 (PAX3), has an essential
role in embryonic melanocyte develop-
ment (Epstein, 2000). In mice, Pax3 is
expressed in the bulge region of adult
hair follicles, where melanocyte stem
cells are found (Nishimura et al., 2002;
Lang et al., 2005). Together with micro-
phthalmia transcription factor (MITF),
PAX3 regulates the balance betweenAbbreviation: PAX3, paired box 3
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